SCRI Development Innovations
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, SCRI Development Innovations sits in the top decile of US sponsors by registered trial count (#191 of 15,742 sponsors by registered trial count).
SCRI Development Innovations: 146 sponsored US clinical trials, 5 recruiting.
SCRI Development Innovations sponsors 146 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 125 completed. 2 of these trials are in Phase 3-4 (later-stage) and 134 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 4 trials.
Top-decile sponsor footprint
SCRI Development Innovations ranks in the top decile of sponsors by registered trial count (#191 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
125 of 141 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
146 total, page 3 of 3
Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme
NCT00544817
First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC
NCT00456261
High-dose Bevacizumab in Advanced Renal Carcinoma Patients
NCT00455975
Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer
NCT00393068
Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
NCT00392821
Treatment of Head & Neck Cancer With Chemotherapy and Radiation
NCT00392704
Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer
NCT00405938
Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
NCT00402883
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
NCT00390611
Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer
NCT00392392
Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site
NCT00360360
Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
NCT00323739
Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies
NCT00315861
5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
NCT00308516
Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer
NCT00305942
Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer
NCT00308529
Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer
NCT00294190
Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer
NCT00297596
Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer
NCT00294931
Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer
NCT00284180
Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer
NCT00284154
A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma
NCT00193492
Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
NCT00193206
Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer
NCT00193453
Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer
NCT00193219
Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer
NCT00193180
Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer
NCT00193414
PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies
NCT00611793
Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site
NCT00193609
Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer
NCT00193271
Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors
NCT00611689
Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma
NCT00193557
Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT00193518
Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer
NCT00193128
Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer
NCT00193427
Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer
NCT00193167
Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer
NCT00193076
Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
NCT00193505
Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer
NCT00193284
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
NCT00193596
Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors
NCT00193583
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
NCT00193479
OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma
NCT00193154
Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients
NCT00193323
Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer
NCT00193037
Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer
NCT00193245
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 29 |
| Phase 2 | 105 |
| Phase 3 | 2 |
What is open in the SCRI Development Innovations pipeline
5 recruiting of 146 indexed (3% open); 125 completed (86%).
Phase mix: 2 late (III/IV) vs 134 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
SCRI Development Innovations: open-pipeline peers nationwide
Peers matched on 146 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
SCRI Development Innovations sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 146 trials (± recruiting share)
- HealthPartners Institute · 146 trials · 8% recruiting
- Mylan Pharmaceuticals · 146 trials · 1% recruiting
- Forest Laboratories · 145 trials · 0% recruiting
- National Institute of Environmental Health Sciences (NIEHS) · 145 trials · 10% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Medtronic MiniMed · 3% recruiting · 29 trials
- Sandoz · 3% recruiting · 29 trials
- Sonova · 3% recruiting · 29 trials
- USDA Beltsville Human Nutrition Research Center · 3% recruiting · 29 trials
Related
What to do with this SCRI Development Innovations page
146 registered trials is a research-attention snapshot, not an endorsement of SCRI Development Innovations or any single study.
- 5 of SCRI Development Innovations's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition SCRI Development Innovations studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
SCRI Development Innovations pipeline card: 146 registered trials from official public datasets.Report a data error.